Pharma Stock Roundup: SNY, RHHBY, PFE's Coronavirus Product Development & Other Updates
Zacks Investment Research | Mar 19, 2020 10:52PM ET
This week Pfizer (NYSE:PFE) signed a letter of intent to jointly develop BioNTech’s potential vaccine for the coronavirus disease, COVID-19. Meanwhile, Roche (OTC:RHHBY) and Regeneron/Sanofi (NASDAQ:SNY) announced plans to study their IL-6 inhibitors, Actemra and Kevzara, respectively, to treat severe COVID-19 infection.
Recap of the Week’s Most Important Stories:
Regeneron/Sanofi & Roche to Evaluate IL-6 Inhibitors for Severe Coronavirus Infection: Regeneron and Sanofi (PA:SASY) announced the initiation of a U.S. based phase II/III study to evaluate their rheumatoid arthritis (RA) drug, ponesimod for treating adults with relapsing forms of multiple sclerosis (RMS). A marketing application seeking approval of ponesimod in Europe was filed earlier this month. The regulatory filings were based on data from the head-to-head OPTIMUM phase III study comparing ponesimod to Sanofi’s MS drug, Aubagio.
Novo Nordisk (CSE:NOVOb) Halts Studies on Haemophilia Candidate: Novo Nordisk (NYSE:NVO) paused three (two phase III and one phase II) ongoing studies investigating its anti-TFPI mAB, concizumab in hemophilia A and B patients with or without inhibitors. The decision was taken due to the occurrence of non-fatal thrombotic events in three patients in the phase III studies. While the company will not recruit any additional patients in the studies, it will also cease further treatment of patients already enrolled in the studies. Novo Nordisk and an independent Data Monitoring Committee are evaluating all available data to decide whether to continue the studies.
The NYSE ARCA Pharmaceutical Index declined 1.9% in the last five trading sessions.
Here is how the seven major stocks performed in the last five trading sessions.
Last week, Lilly recorded the highest increase (5.6%) while Glaxo declined the most (7.8%).
In the past six months, Lilly has risen the most (16.6%) while Glaxo declined the most (19.7%).
(See the last pharma stock roundup here: Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.